IMC P115C
Alternative Names: IMC-P115CLatest Information Update: 11 Mar 2024
At a glance
- Originator Immunocore
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Feb 2024 Immunocore plans to file an CTA application for Solid tumours in the middle of 2024 (Immunocore pipeline, September 2023)
- 28 Feb 2024 Immunocore announces intention to file an IND application for Solid tumours in the middle of 2024
- 17 Jan 2023 Pharmacokinetics data from a preclinical study in Solid tumours released by Immunocore